The experiment is attended by twelve patients with incurable disease Shtargardta, that happens in one out of ten thousand individuals and ends up in gradual loss of vision.
Scientists at Moorfields Eye Hospital in London received permission to conduct the primary clinical trials in Europe using human embryonic stem cells.
Tests can check the security procedures, that are predicated within the introduction of retinal pigment cells of patients with epithelial stem cells derived from human embryos. The organization’s representatives are assured that this may be
“Another milestone within the development of regenerative drugs.”
“There may be a real chance that individuals who are blind due to issues with the retina full of disease or age Shtargardta-related macular degeneration might get pleasure from transplantation of retinal cells,” – says Professor James Bainbridge from the hospital, Moorfields Eye.
Earlier this year, the National Institute of Health analysis (NIHR) has allotted and Moorfields Hospital Institute of Ophthalmology at University school London, twenty six million pounds to develop new treatments for individuals with eye disease, that threatens the loss of vision.
Note that currently theU.S.company Geron already using embryonic stem cells to treat patients with spinal twine injuries.